An immunotherapy drug could help some cancer patients live years longer without the disease worsening or recurring, according to a new trial.
The study revealed that pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care. It also slashed the risk of the disease returning in another part of the body.
